Molecular advances to treat cancer of the brain

H. M. Fathallah-Shaykh, L. J. Zhao, B. Mickey, A. I. Kafrouni

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

Malignant primary and metastatic brain tumours continue to be associated with poor prognosis. Nevertheless, recent advances in molecular medicine, specifically in the strategies of gene therapy, targeting tumour cells, anti-angiogenesis and immunotherapy, have created novel tools that may be of therapeutic value. To date, gene therapy trials have not yet demonstrated clinical efficacy because of inherent defects in vector design. Despite this, advances in adenoviral technology, namely the helper dependent adenoviral constructs (gutless) and the uncovering of brain parenchymal cells as effective and necessary targets for antitumour benefits of adenoviral-mediated gene transfer, suggest that developments in vector design may be approaching the point of clinical utility. Targeting tumour cells refers to strategies that destroy malignant but spare normal cells. A new assortment of oncolytic viruses have emerged, capable of specific lysis of cancer tissue while sparing normal cells and propagating until they reach the tumour borders. Furthermore, peptides have been transformed into bullets that specifically seek and destroy cancer cells. The concept of tumour angiogenesis has been challenged by new but still very controversial findings that tumour cells themselves may form blood channels. These results may lead to the redirecting of the molecular targets toward anti-angiogenesis in some tumours including glioblastoma multiform. Unfortunately, our knowledge regarding the immunological ignorance of the tumour is still limited. Even so, newly discovered molecules have shed light on novel pathways leading to the escape of the tumour from the immune system. Finally, significant limitations in our current experimental tumour models may soon be overcome by firstly, the development of models of reproducible organ-specific rumours in non-inbred animals and secondly applying genomics to individualise therapy for a particular tumour in a specific patient.

Original languageEnglish (US)
Pages (from-to)1207-1215
Number of pages9
JournalExpert Opinion on Investigational Drugs
Volume9
Issue number6
StatePublished - 2000

Fingerprint

Brain Neoplasms
Neoplasms
Genetic Therapy
Oncolytic Viruses
Tumor Escape
Molecular Medicine
Gene Targeting
Glioblastoma
Genomics
Immunotherapy
Immune System
Theoretical Models
Technology
Peptides
Brain

Keywords

  • Adenovirus
  • Angiogenesis
  • Animal models
  • Brain
  • Cytokines
  • Gene microarray
  • Gene therapy
  • Glioma
  • Immunotherapy
  • Oncolytic virus
  • Peptides
  • Tumour

ASJC Scopus subject areas

  • Pharmacology

Cite this

Fathallah-Shaykh, H. M., Zhao, L. J., Mickey, B., & Kafrouni, A. I. (2000). Molecular advances to treat cancer of the brain. Expert Opinion on Investigational Drugs, 9(6), 1207-1215.

Molecular advances to treat cancer of the brain. / Fathallah-Shaykh, H. M.; Zhao, L. J.; Mickey, B.; Kafrouni, A. I.

In: Expert Opinion on Investigational Drugs, Vol. 9, No. 6, 2000, p. 1207-1215.

Research output: Contribution to journalArticle

Fathallah-Shaykh, HM, Zhao, LJ, Mickey, B & Kafrouni, AI 2000, 'Molecular advances to treat cancer of the brain', Expert Opinion on Investigational Drugs, vol. 9, no. 6, pp. 1207-1215.
Fathallah-Shaykh HM, Zhao LJ, Mickey B, Kafrouni AI. Molecular advances to treat cancer of the brain. Expert Opinion on Investigational Drugs. 2000;9(6):1207-1215.
Fathallah-Shaykh, H. M. ; Zhao, L. J. ; Mickey, B. ; Kafrouni, A. I. / Molecular advances to treat cancer of the brain. In: Expert Opinion on Investigational Drugs. 2000 ; Vol. 9, No. 6. pp. 1207-1215.
@article{e601d2ea54964dcfae4fa1aabd4b9f34,
title = "Molecular advances to treat cancer of the brain",
abstract = "Malignant primary and metastatic brain tumours continue to be associated with poor prognosis. Nevertheless, recent advances in molecular medicine, specifically in the strategies of gene therapy, targeting tumour cells, anti-angiogenesis and immunotherapy, have created novel tools that may be of therapeutic value. To date, gene therapy trials have not yet demonstrated clinical efficacy because of inherent defects in vector design. Despite this, advances in adenoviral technology, namely the helper dependent adenoviral constructs (gutless) and the uncovering of brain parenchymal cells as effective and necessary targets for antitumour benefits of adenoviral-mediated gene transfer, suggest that developments in vector design may be approaching the point of clinical utility. Targeting tumour cells refers to strategies that destroy malignant but spare normal cells. A new assortment of oncolytic viruses have emerged, capable of specific lysis of cancer tissue while sparing normal cells and propagating until they reach the tumour borders. Furthermore, peptides have been transformed into bullets that specifically seek and destroy cancer cells. The concept of tumour angiogenesis has been challenged by new but still very controversial findings that tumour cells themselves may form blood channels. These results may lead to the redirecting of the molecular targets toward anti-angiogenesis in some tumours including glioblastoma multiform. Unfortunately, our knowledge regarding the immunological ignorance of the tumour is still limited. Even so, newly discovered molecules have shed light on novel pathways leading to the escape of the tumour from the immune system. Finally, significant limitations in our current experimental tumour models may soon be overcome by firstly, the development of models of reproducible organ-specific rumours in non-inbred animals and secondly applying genomics to individualise therapy for a particular tumour in a specific patient.",
keywords = "Adenovirus, Angiogenesis, Animal models, Brain, Cytokines, Gene microarray, Gene therapy, Glioma, Immunotherapy, Oncolytic virus, Peptides, Tumour",
author = "Fathallah-Shaykh, {H. M.} and Zhao, {L. J.} and B. Mickey and Kafrouni, {A. I.}",
year = "2000",
language = "English (US)",
volume = "9",
pages = "1207--1215",
journal = "Current Opinion in Investigational Drugs",
issn = "1354-3784",
publisher = "Informa Healthcare",
number = "6",

}

TY - JOUR

T1 - Molecular advances to treat cancer of the brain

AU - Fathallah-Shaykh, H. M.

AU - Zhao, L. J.

AU - Mickey, B.

AU - Kafrouni, A. I.

PY - 2000

Y1 - 2000

N2 - Malignant primary and metastatic brain tumours continue to be associated with poor prognosis. Nevertheless, recent advances in molecular medicine, specifically in the strategies of gene therapy, targeting tumour cells, anti-angiogenesis and immunotherapy, have created novel tools that may be of therapeutic value. To date, gene therapy trials have not yet demonstrated clinical efficacy because of inherent defects in vector design. Despite this, advances in adenoviral technology, namely the helper dependent adenoviral constructs (gutless) and the uncovering of brain parenchymal cells as effective and necessary targets for antitumour benefits of adenoviral-mediated gene transfer, suggest that developments in vector design may be approaching the point of clinical utility. Targeting tumour cells refers to strategies that destroy malignant but spare normal cells. A new assortment of oncolytic viruses have emerged, capable of specific lysis of cancer tissue while sparing normal cells and propagating until they reach the tumour borders. Furthermore, peptides have been transformed into bullets that specifically seek and destroy cancer cells. The concept of tumour angiogenesis has been challenged by new but still very controversial findings that tumour cells themselves may form blood channels. These results may lead to the redirecting of the molecular targets toward anti-angiogenesis in some tumours including glioblastoma multiform. Unfortunately, our knowledge regarding the immunological ignorance of the tumour is still limited. Even so, newly discovered molecules have shed light on novel pathways leading to the escape of the tumour from the immune system. Finally, significant limitations in our current experimental tumour models may soon be overcome by firstly, the development of models of reproducible organ-specific rumours in non-inbred animals and secondly applying genomics to individualise therapy for a particular tumour in a specific patient.

AB - Malignant primary and metastatic brain tumours continue to be associated with poor prognosis. Nevertheless, recent advances in molecular medicine, specifically in the strategies of gene therapy, targeting tumour cells, anti-angiogenesis and immunotherapy, have created novel tools that may be of therapeutic value. To date, gene therapy trials have not yet demonstrated clinical efficacy because of inherent defects in vector design. Despite this, advances in adenoviral technology, namely the helper dependent adenoviral constructs (gutless) and the uncovering of brain parenchymal cells as effective and necessary targets for antitumour benefits of adenoviral-mediated gene transfer, suggest that developments in vector design may be approaching the point of clinical utility. Targeting tumour cells refers to strategies that destroy malignant but spare normal cells. A new assortment of oncolytic viruses have emerged, capable of specific lysis of cancer tissue while sparing normal cells and propagating until they reach the tumour borders. Furthermore, peptides have been transformed into bullets that specifically seek and destroy cancer cells. The concept of tumour angiogenesis has been challenged by new but still very controversial findings that tumour cells themselves may form blood channels. These results may lead to the redirecting of the molecular targets toward anti-angiogenesis in some tumours including glioblastoma multiform. Unfortunately, our knowledge regarding the immunological ignorance of the tumour is still limited. Even so, newly discovered molecules have shed light on novel pathways leading to the escape of the tumour from the immune system. Finally, significant limitations in our current experimental tumour models may soon be overcome by firstly, the development of models of reproducible organ-specific rumours in non-inbred animals and secondly applying genomics to individualise therapy for a particular tumour in a specific patient.

KW - Adenovirus

KW - Angiogenesis

KW - Animal models

KW - Brain

KW - Cytokines

KW - Gene microarray

KW - Gene therapy

KW - Glioma

KW - Immunotherapy

KW - Oncolytic virus

KW - Peptides

KW - Tumour

UR - http://www.scopus.com/inward/record.url?scp=0034128233&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0034128233&partnerID=8YFLogxK

M3 - Article

VL - 9

SP - 1207

EP - 1215

JO - Current Opinion in Investigational Drugs

JF - Current Opinion in Investigational Drugs

SN - 1354-3784

IS - 6

ER -